Karuna Therapeutics (NASDAQ: KRTX) is one of 618 public companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its peers? We will compare Karuna Therapeutics to similar businesses based on the strength of its earnings, dividends, analyst recommendations, risk, profitability, valuation and institutional ownership.
Insider and Institutional Ownership
63.9% of Karuna Therapeutics shares are held by institutional investors. Comparatively, 45.7% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 18.1% of Karuna Therapeutics shares are held by company insiders. Comparatively, 15.5% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
This is a summary of current recommendations for Karuna Therapeutics and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Karuna Therapeutics Competitors||6716||18624||35987||1437||2.51|
Karuna Therapeutics currently has a consensus target price of $117.73, indicating a potential upside of 8.61%. As a group, “Pharmaceutical preparations” companies have a potential upside of 37.80%. Given Karuna Therapeutics’ peers higher possible upside, analysts clearly believe Karuna Therapeutics has less favorable growth aspects than its peers.
This table compares Karuna Therapeutics and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Karuna Therapeutics Competitors||-3,409.24%||-244.96%||-33.16%|
Earnings and Valuation
This table compares Karuna Therapeutics and its peers revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Karuna Therapeutics||N/A||-$43.96 million||-29.45|
|Karuna Therapeutics Competitors||$2.12 billion||$260.75 million||0.59|
Karuna Therapeutics’ peers have higher revenue and earnings than Karuna Therapeutics. Karuna Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Karuna Therapeutics beats its peers on 7 of the 12 factors compared.
Karuna Therapeutics Company Profile
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, primarily focuses on developing novel therapies to address disabling neuropsychiatric conditions characterized by significant unmet medical needs. The company's lead product candidate is KarXT, an oral modulator that is in Phase II clinical trial for the treatment of acute psychosis in patients with schizophrenia, as well as in Phase Ib clinical trial for the treatment of central nervous system disorders, such as cognitive and negative symptoms, Alzheimer's, and pain. It also focuses on developing other muscarinic-targeted drug candidates. Karuna Pharmaceuticals, Inc. has a license agreement with Eli Lilly and Company; and patent license agreement with PureTech Health LLC. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was founded in 2009 and is headquartered in Boston, Massachusetts. Karuna Therapeutics, Inc. operates as a subsidiary of PureTech Health plc.
Receive News & Ratings for Karuna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karuna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.